See the latest news and media coverage for Alnylam. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biopharmaceutical company developing RNA interference medicines
alnylam.comLast updated
In short: Alnylam reported third-quarter revenue growth and expanded its nucresiran heart trial.
The board approved buying back up to $1 billion of common stock, about $500 million by end-2026 and the rest in 2027. Chief Commercialization Officer Tolga Tanguler departs.
Total revenues reached $1.46 billion with a 52% increase in product revenue. The company also highlighted pipeline advances for nucresiran and brezosiran while reiterating full-year guidance.
Brezosiran demonstrated deep and durable huntingtin reduction with encouraging safety. A pivotal study is planned for 2027.
Q1 net product revenues reached $1.036 billion, a 121% increase year-over-year, driven by TTR franchise momentum. The company reiterates full-year guidance of $4.9 to $5.3 billion.
Pushkal Garg, Chief Research and Development Officer at Alnylam, said: "These data reinforce the strength of TTR silencing as a foundational approach to ATTR-CM care...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that its Board of Directors has authorized a $1 billion share repurchase program...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended September 30, 2026, and...
Alnylam Pharmaceuticals, Inc. ( ALNY) reported its third-quarter 2026 earnings and revenue, supported by continued growth in its transthyretin (TTR) franchise, particularly AMVUTTRA. The company...
Track Alnylam and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Alnylam and other trending companies.
